Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Multicenter, Proof-Of-Concept Study Of Intravitreal AL-78898A In Patients With Geographic Atrophy (GA) Associated With Age-Related Macular Degeneration (AMD)

This study has been terminated.
(Management Decision)
Information provided by (Responsible Party):
Alcon Research Identifier:
First received: May 18, 2012
Last updated: December 3, 2013
Last verified: December 2013
The purpose of this study was to to demonstrate superiority of AL-78898A intravitreal (IVT) injections compared to sham injections by assessing mean geographic atrophy (GA) lesion size change from baseline at Month 12.

Condition Intervention Phase
Geographic Atrophy
Drug: Al-78898A
Drug: Sham injection
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Participant)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Single-Masked, Sham-Controlled, Proof-of-Concept Study of Intravitreal AL-78898A in Patients With Bilateral Geographic Atrophy (GA) Associated With Age-Related Macular Degeneration (AMD)

Resource links provided by NLM:

Further study details as provided by Alcon Research:

Primary Outcome Measures:
  • Mean Change From Baseline in GA Lesion Size at Month 12 as Assessed With FAF Imaging [ Time Frame: Day 0 (injection visit), Month 12 ]
    Efficacy analysis was not conducted due to the termination of the study prior to the primary and secondary efficacy endpoints and the small number of enrolled patients.

Secondary Outcome Measures:
  • Yearly GA Lesion Size Growth Rate [ Time Frame: Baseline (Day 0), up to Month 12 ]
    Efficacy analysis was not conducted due to the termination of the study prior to the primary and secondary efficacy endpoints and the small number of enrolled patients.

  • Mean Change From Baseline in BCVA at Month 12 [ Time Frame: Baseline (Day 0), Month 12 ]
    Efficacy analysis was not conducted due to the termination of the study prior to the primary and secondary efficacy endpoints and the small number of enrolled patients.

Enrollment: 10
Study Start Date: June 2012
Study Completion Date: November 2012
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AL-78898A
1 intravitreal injection per month for up to 12 months
Drug: Al-78898A
0.400 milligrams (mg) per 50 microliters (μL) administered as an intravitreal injection
Sham Comparator: Sham Injection
1 mock injection per month for 12 months
Drug: Sham injection
Mock injection administered as an empty hub without needle

Detailed Description:
Participants meeting inclusion/exclusion criteria were randomized in a 2:1 ratio to receive AL-78898A or a sham injection. The study eye was assessed before and after each injection to ensure that the injection procedure and/or study medication had not endangered the health of the eye. The Investigator determined each month whether the patient was eligible to receive the next injection. The study was terminated due to a high likelihood that continued enrollment would reach the predefined study stopping criteria based upon the number of patients with drug deposit formation, which made an assessment of efficacy futile.

Ages Eligible for Study:   55 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Ability to provide informed consent and comply with the protocol.
  • Diagnosis of bilateral geographic atrophy (GA) of the macula secondary to age-related macular degeneration, confirmed within 14 days prior to randomization.
  • Study eye: Maximum best-corrected visual acuity (BCVA) of 55 letters (20/80 Snellen equivalent) and a minimum BCVA of 20 letters (20/400 Snellen equivalent) at screening
  • BCVA of 20 letters (20/400 Snellen equivalent) or better in the non treated eye at screening without conditions other than AMD that, in the opinion of the investigator, could cause a rapid loss of vision.
  • Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

  • Any history or current evidence of exudative ("wet") AMD in study eye.
  • Retinal disease other than AMD in the study eye.
  • Any ophthalmologic condition in study eye that reduces the clarity of the media and that, in the opinion of the Investigator interferes with ophthalmologic examination, such as advanced cataract or corneal abnormalities.
  • Any ophthalmologic condition in study eye that prevents adequate imaging of the retina judged by the site or reading center.
  • A history or current medical diagnosis of glaucoma or ocular hypertension in study eye.
  • Any ophthalmic condition in study eye that may require surgery during the study period.
  • Current ocular or periocular infection in the study eye.
  • History of any disease or current use of medication expected to cause systemic or ocular immunosuppression, such as RESTASIS®.
  • History of uveitis or endophthalmitis in the study eye.
  • History of intraocular surgery (including cataract surgery) in the study eye within 90 days prior to dosing.
  • History of intravitreal or periocular injection in the study eye at anytime.
  • Participation in another interventional clinical study, or use of any experimental treatment for AMD or any other investigational new drug within 6 weeks or during active period of drug (whichever is longer) prior to the start of study treatment.
  • History of any medical or psychiatric condition, or substance abuse, that in the Investigator's opinion is likely to interfere with the patient's participation in the study, or likely to cause serious adverse events during the study.
  • Women of child bearing potential UNLESS they are using a highly effective method of birth control.
  • Known or suspected allergy or hypersensitivity to fluorescein or other injectables.
  • Other protocol-defined exclusion criteria may apply.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01603043

Sponsors and Collaborators
Alcon Research
Study Director: Mehdi Hosseini, MD Alcon Research
  More Information

Responsible Party: Alcon Research Identifier: NCT01603043     History of Changes
Other Study ID Numbers: C-12-020
Study First Received: May 18, 2012
Results First Received: December 3, 2013
Last Updated: December 3, 2013

Keywords provided by Alcon Research:
Geographic Atrophy
Age-Related Macular Degeneration
Intravitreal injection

Additional relevant MeSH terms:
Macular Degeneration
Geographic Atrophy
Retinal Degeneration
Retinal Diseases
Eye Diseases
Pathological Conditions, Anatomical processed this record on May 25, 2017